Related references
Note: Only part of the references are listed.Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Michael J. Satlin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial
Richard R. Watkins et al.
CLINICAL INFECTIOUS DISEASES (2023)
Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
Monirul I. Sajib et al.
ANTIBIOTICS-BASEL (2023)
Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
Gabriele Palermo et al.
ANTIBIOTICS-BASEL (2023)
Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study
Emanuele Rando et al.
JAC-ANTIMICROBIAL RESISTANCE (2023)
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
Dennis Nurjadi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Mical Paul et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update
Emily N. Drwiega et al.
CLINICAL PHARMACOKINETICS (2022)
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
Nao Kawaguchi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Marco Falcone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis et al.
ANTIBIOTICS-BASEL (2022)
Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022
Marco Coppi et al.
EUROSURVEILLANCE (2022)
Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
Silvia Corcione et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Patricia J. Simner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
Alexandre Bleibtreu et al.
MICROORGANISMS (2021)
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens
Jacob E Choby et al.
LANCET INFECTIOUS DISEASES (2021)
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
Marianna Meschiari et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
Renato Pascale et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
Renato Pascale et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
Pranita D. Tamma et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Takayuki Katsube et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
Paul E. Stevens et al.
ANNALS OF INTERNAL MEDICINE (2013)
Validation of a modified Early Warning Score in medical admissions
CP Subbe et al.
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS (2001)